QFT · Digital Therapeutic Software For Attention Deficit Hyperactivity Disorder

Obstetrics/Gynecology · 21 CFR 882.5803 · Class 2

Overview

Product CodeQFT
Device NameDigital Therapeutic Software For Attention Deficit Hyperactivity Disorder
Regulation21 CFR 882.5803
Device ClassClass 2
Review PanelObstetrics/Gynecology

Identification

A digital therapy device for Attention Deficit Hyperactivity Disorder (ADHD) is a software intended to provide therapy for ADHD or any of its individual symptoms as an adjunct to clinician supervised treatment.

Classification Rationale

Class II (special controls). The special controls for this device are:

Special Controls

In combination with the general controls of the FD&C Act, the digital therapy device for Attention Deficit Hyperactivity Disorder is subject to the following special controls:

*Classification.* Class II (special controls). The special controls for this device are:(1) Clinical performance testing must demonstrate and document the following under the labeled conditions for use, which include considerations for the ability of the device to: (i) Use a validated measure to evaluate effectiveness of device to provide therapy for ADHD or any of its individual symptoms; and (ii) Capture all adverse events. (2) Software must be described and provided in a clear and detailed manner to include all features and functions of the software implementing the digital therapy. Software verification, validation, and hazard analysis must also be provided. (3) The labeling must include the following items: (i) Patient and physician labeling must include instructions for use, including images that demonstrate how to interact with the device; (ii) Patient and physician labeling must list the minimum operating system (OS) requirements that support the software of the device; (iii) Patient and physician labeling must include a warning that the digital therapy device is not intended for use as a standalone therapeutic device; (iv) Patient and physician labeling must include a warning that the digital therapy device does not represent a substitution for the patient's medication; and (v) Physician labeling must include a summary of the clinical performance testing conducted with the device.

Recent Cleared Devices (4 of 4)

RecordDevice NameApplicantDecision DateDecision
K243729PrismiraLumos Labs, Inc.Jun 13, 2025SESE
K233496EndeavorOTCAkili Interactive Labs, Inc.Jun 14, 2024SESE
K231337EndeavorRxAkili Interactive Labs, Inc.Dec 13, 2023SESE
DEN200026EndeavorRxAkili Interactive Labs, Inc.Jun 15, 2020DENG

Top Applicants

Innolitics

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...